Research-use wording: This may not mean patient-ready medicine
The MHRA approval confirms the medicines authorisation, not a universal retail price
GLP-1s are approved for weight loss in adults who have a body mass index of 30 or higher, and those who are overweight with a body mass index of 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol and type 2 diabetes
GLP-1 medications offer an evidence-based approach that supports long-term results by calming hunger signals, stabilizing blood sugar patterns, and helping patients feel more in control of their daily choices
Pharmacy Times: From your perspective, what are the most important clinical considerations when GLP-1s are used by athletes (eg, gastrointestinal adverse effects, hydration/electrolytes, energy availability, timing around training/competition)
Neuron 88 , 957972 (2015)